A recent study found the drug combination lenalidomide + rituximab is a durable, effective and safe alternative to the standard regimen combining rituximab and chemotherapy.
The treatment is approved for patients who have a moderate to high risk of recurrence, following nephrectomy or nephrectomy accompanied by surgical resection of metastatic lesions.
Will attempt to determine which children with resolved anaphylaxis in the emergency department should be observed for biphasic anaphylaxis and for how long.
